These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 34800290)

  • 1. Alterations in gut microbiota and elevated serum bilirubin in primary biliary cholangitis patients treated with ursodeoxycholic acid.
    Han W; Huang C; Zhang Q; Tao S; Hu X; Xu J; Jiang R; Xu B; Liu Y; Hou J
    Eur J Clin Invest; 2022 Feb; 52(2):e13714. PubMed ID: 34800290
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gut microbial profile is altered in primary biliary cholangitis and partially restored after UDCA therapy.
    Tang R; Wei Y; Li Y; Chen W; Chen H; Wang Q; Yang F; Miao Q; Xiao X; Zhang H; Lian M; Jiang X; Zhang J; Cao Q; Fan Z; Wu M; Qiu D; Fang JY; Ansari A; Gershwin ME; Ma X
    Gut; 2018 Mar; 67(3):534-541. PubMed ID: 28213609
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid.
    Kuiper EM; Hansen BE; de Vries RA; den Ouden-Muller JW; van Ditzhuijsen TJ; Haagsma EB; Houben MH; Witteman BJ; van Erpecum KJ; van Buuren HR;
    Gastroenterology; 2009 Apr; 136(4):1281-7. PubMed ID: 19208346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score.
    Carbone M; Nardi A; Flack S; Carpino G; Varvaropoulou N; Gavrila C; Spicer A; Badrock J; Bernuzzi F; Cardinale V; Ainsworth HF; Heneghan MA; Thorburn D; Bathgate A; Jones R; Neuberger JM; Battezzati PM; Zuin M; Taylor-Robinson S; Donato MF; Kirby J; Mitchell-Thain R; Floreani A; Sampaziotis F; Muratori L; Alvaro D; Marzioni M; Miele L; Marra F; Giannini E; Gaudio E; Ronca V; Bonato G; Cristoferi L; Malinverno F; Gerussi A; Stocken DD; Cordell HJ; Hirschfield GM; Alexander GJ; Sandford RN; Jones DE; Invernizzi P; Mells GF;
    Lancet Gastroenterol Hepatol; 2018 Sep; 3(9):626-634. PubMed ID: 30017646
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis.
    Corpechot C; Abenavoli L; Rabahi N; Chrétien Y; Andréani T; Johanet C; Chazouillères O; Poupon R
    Hepatology; 2008 Sep; 48(3):871-7. PubMed ID: 18752324
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic factors and long-term effects of ursodeoxycholic acid on liver biochemical parameters in patients with primary biliary cirrhosis. Dutch Multi-Centre PBC Study Group.
    van Hoogstraten HJ; Hansen BE; van Buuren HR; ten Kate FJ; van Berge-Henegouwen GP; Schalm SW
    J Hepatol; 1999 Aug; 31(2):256-62. PubMed ID: 10453938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bacterial and metabolic phenotypes associated with inadequate response to ursodeoxycholic acid treatment in primary biliary cholangitis.
    Martinez-Gili L; Pechlivanis A; McDonald JAK; Begum S; Badrock J; Dyson JK; Jones R; Hirschfield G; Ryder SD; Sandford R; Rushbrook S; Thorburn D; Taylor-Robinson SD; Crossey MME; Marchesi JR; Mells G; Holmes E; Jones D
    Gut Microbes; 2023; 15(1):2208501. PubMed ID: 37191344
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Goals of Treatment for Improved Survival in Primary Biliary Cholangitis: Treatment Target Should Be Bilirubin Within the Normal Range and Normalization of Alkaline Phosphatase.
    Murillo Perez CF; Harms MH; Lindor KD; van Buuren HR; Hirschfield GM; Corpechot C; van der Meer AJ; Feld JJ; Gulamhusein A; Lammers WJ; Ponsioen CY; Carbone M; Mason AL; Mayo MJ; Invernizzi P; Battezzati PM; Floreani A; Lleo A; Nevens F; Kowdley KV; Bruns T; Dalekos GN; Gatselis NK; Thorburn D; Trivedi PJ; Verhelst X; Parés A; Janssen HLA; Hansen BE;
    Am J Gastroenterol; 2020 Jul; 115(7):1066-1074. PubMed ID: 32618657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of ursodeoxycholic acid in patients with primary biliary cirrhosis: sense or nonsense.
    Van Den Bogaert E; Francque S; Pelckmans P; Michielsen P
    Acta Gastroenterol Belg; 2003; 66(4):283-7. PubMed ID: 14989050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognosis of ursodeoxycholic Acid-treated patients with primary biliary cirrhosis. Results of a 10-yr cohort study involving 297 patients.
    ter Borg PC; Schalm SW; Hansen BE; van Buuren HR;
    Am J Gastroenterol; 2006 Sep; 101(9):2044-50. PubMed ID: 16848809
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical significance of serum bilirubin levels under ursodeoxycholic acid therapy in patients with primary biliary cirrhosis.
    Bonnand AM; Heathcote EJ; Lindor KD; Poupon RE
    Hepatology; 1999 Jan; 29(1):39-43. PubMed ID: 9862847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-Term Fenofibrate Treatment in Primary Biliary Cholangitis Improves Biochemistry but Not the UK-PBC Risk Score.
    Hegade VS; Khanna A; Walker LJ; Wong LL; Dyson JK; Jones DEJ
    Dig Dis Sci; 2016 Oct; 61(10):3037-3044. PubMed ID: 27435324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Worse Response to Ursodeoxycholic Acid in Primary Biliary Cholangitis Patients with Autoimmune Hepatitis Features.
    Wen M; Men R; Fan X; Shen Y; Ni P; Hu Z; Yang L
    Dig Dis; 2021; 39(4):366-374. PubMed ID: 33238269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence factors and a predictive scoring model for measuring the biochemical response of primary biliary cholangitis to ursodeoxycholic acid treatment.
    Chen J; Xue D; Gao F; Tao L; Li Y; Zhang Q; Wang R; Sun L; Yang X; Liu Y; Zhu B; Niu S; Wang X
    Eur J Gastroenterol Hepatol; 2018 Nov; 30(11):1352-1360. PubMed ID: 29889683
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment of cholestatic liver disease].
    Pleşa A
    Rev Med Chir Soc Med Nat Iasi; 2003; 107(4):733-6. PubMed ID: 14756010
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimizing biochemical markers as endpoints for clinical trials in primary biliary cirrhosis.
    Momah N; Silveira MG; Jorgensen R; Sinakos E; Lindor KD
    Liver Int; 2012 May; 32(5):790-5. PubMed ID: 22136310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Natural History of Primary Biliary Cholangitis in the Ursodeoxycholic Acid Era: Role of Scoring Systems.
    Goel A; Kim WR
    Clin Liver Dis; 2018 Aug; 22(3):563-578. PubMed ID: 30259853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RANK/RANKL Acts as a Protective Factor by Targeting Cholangiocytes in Primary Biliary Cholangitis.
    Hao YL; Bian ZL; Ju LL; Liu Y; Qin G
    Dig Dis Sci; 2020 Feb; 65(2):470-479. PubMed ID: 31377883
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of primary biliary cholangitis with ursodeoxycholic acid, prednisolone and immunosuppressants in patients not responding to ursodeoxycholic acid alone and the prognostic indicators.
    Qian JD; Yao TT; Wang Y; Wang GQ
    Clin Res Hepatol Gastroenterol; 2020 Nov; 44(6):874-884. PubMed ID: 32305248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biochemical response to ursodeoxycholic acid among PBC patients: a nationwide population-based study.
    Örnolfsson KT; Lund SH; Olafsson S; Bergmann OM; Björnsson ES
    Scand J Gastroenterol; 2019 May; 54(5):609-616. PubMed ID: 31074667
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.